← brief for 2026-09-09 · Slowing decline

Orforglipron and the Kidney: A Promise or Disappointment? The Need for Trials Examining Renal Outcomes.

Article No results yet Peer reviewed

Key takeaways

Orforglipron is the first GLP-1 drug of its class that comes as a pill instead of a shot. This review argues it could suit people with chronic kidney disease because the liver clears it, so damaged kidneys do not have to. The authors searched the published literature and the trial registry through May 2026 and found no trial testing whether the drug protects kidneys. They are calling for one. There are no kidney results yet.

Who did this work

Shah J · Luna Ceron E · Payan-Schober F · Hechanova LA · Clegg DJ · Palmer BF

Source

Article · PubMed, the drug frontier · 2026 Sep 9
https://pubmed.ncbi.nlm.nih.gov/42715144/